GlassScriptPhysician profile
Michelle Zikusoka
NPI 1003953290
$1,310.21
in general payments reported to CMS, 2019-2025
17 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $153 · 2021: $81.25 · 2022: $190 · 2023: $312 · 2024: $74.93 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $210.05 | 2020-2024 | Xarelto |
| Abiomed | $163.00 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $146.02 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $126.86 | 2020-2023 | Lifevest |
| Boston Scientific Corporation | $123.91 | 2019-2025 | Watchman Flx |
| Pfizer INC. | $88.13 | 2020-2025 | |
| Amgen INC. | $80.45 | 2020-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $74.63 | 2023-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $72.25 | 2025 | |
| Atricure, INC. | $43.82 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Inspire Medical Systems, INC. | $42.03 | 2025 | Inspire |
| Heartflow, INC. | $39.19 | 2025 | |
| Edwards Lifesciences Corporation | $30.52 | 2019 | |
| Impulse Dynamics (USA) INC. | $24.95 | 2022 | |
| Esperion Therapeutics, INC. | $15.35 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Zikusoka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.